ASCO GI 2021 | FIGHT: bemarituzumab + mFOLFOX6 in first-line advanced gastric cancer

Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, discusses the results of the FIGHT study (NCT03694522), a double-blind placebo-controlled Phase II study of bemarituzumab, an FGFR2b targeting antibody in combination with modified FOLFOX6 (mFOLFOX6) in the first-line treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).